Liraglutide vs Alpha-GPC
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideCognitive Enhancement
Alpha-GPC- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Alpha-GPC is the most bioavailable form of choline, readily crossing the blood-brain barrier to rapidly increase acetylcholine levels. It enhances cognitive performance, supports GH secretion, and is used as an essential complement to many nootropic peptides (especially those that increase acetylcholine demand like Noopept and Dihexa).
- Half-Life
- ~13 hours (once-daily dosing)
- ~4–6 hours
- Admin Route
- SubQ
- Oral, SubQ
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 300–600 mg
- Frequency
- Once daily
- 1–2x daily
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Rapidly raises brain acetylcholine levels
- Enhances memory formation and recall
- Prevents headaches from nootropic peptides (choline donor)
- Stimulates growth hormone secretion (modest)
- Improves attention and processing speed
- Neuroprotective in Alzheimer's and cognitive decline
- Approved in Europe for Alzheimer's therapy
- Enhances power output in athletes (pre-workout)
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Headache (paradoxically, from excess acetylcholine at very high doses)
- Nausea at doses > 1200 mg
- Dizziness
- Fatigue at high doses
- +1 more
- Stacks With
- —
- —